Wojcicki Foundation Launches with $150M+ to Fight Lung Cancer

LOS ALTOS, CA – May 12, 2026 – A formidable new force in the war on cancer launched today, as the Susan Wojcicki Foundation announced its mission to accelerate the early detection and prevention of lung cancer. Inspired by the personal battle of its namesake, the former long-time CEO of YouTube, the foundation begins its work with over $150 million in founding support and major commitments from some of the biggest names in technology and philanthropy, including Google.org, Melinda French Gates, and Salesforce.

The initiative was born from tragedy. Susan Wojcicki, a titan of Silicon Valley, received a late-stage lung cancer diagnosis in 2022 despite having no known risk factors, a devastating reminder that the disease is often caught far too late. Now, her family is channeling that experience into a focused, action-oriented effort to change the future of the world's deadliest cancer.

A Personal Mission with a Global Reach

The foundation is a deeply personal endeavor for the Wojcicki and Troper families, who have committed $150 million to establish the organization. The leadership includes Susan's husband, Dennis Troper, and her sisters, Janet Wojcicki and Anne Wojcicki, the co-founder and CEO of the genetics company 23andMe. Their collective experience spans technology, science, and philanthropy, creating a powerful nexus for change.

"This work is deeply personal for our family," said Troper in a statement. "Through the Foundation, we are committed to helping advance earlier detection and supporting those working to change the future of this disease—from researchers and clinicians bringing the science to life to the advocates and creators helping spread awareness of a disease that takes the lives of too many. We are energized by the opportunity to change outcomes for millions of families."

This personal drive is amplified by a powerful coalition of partners. Google.org is committing funds to apply artificial intelligence to better identify risk and enable earlier detection. Melinda French Gates, founder of Pivotal, and Salesforce, where Susan Wojcicki was a longtime board member, have also made significant multi-million dollar contributions. This convergence of personal mission and corporate might signals a serious new front in a long-fought battle.

Redefining Risk: Beyond the Smoker Stereotype

A core tenet of the foundation's mission is to challenge and update the public perception of who gets lung cancer. For decades, the disease has been almost exclusively linked to smoking, but the reality is far more complex and is rapidly changing. The foundation's launch materials highlight a critical and often overlooked fact: an increasing share of diagnoses are in younger people, women, and those who have never smoked.

Data from leading health organizations validates this urgent concern. Lung cancer in people who have never smoked now accounts for 10% to 20% of all cases. If classified as its own disease, it would rank as the seventh most common cancer worldwide. This trend is particularly pronounced in women, especially those of East Asian descent, who account for 60-80% of non-smoking lung cancer cases in Asia.

The current gold standard for screening, the low-dose CT (LDCT) scan, is recommended only for a narrow band of high-risk individuals—typically older, long-term heavy smokers. While effective for that group, uptake remains below 20%, and it leaves the growing population of non-smoking and younger patients without a viable path to early detection. This is the gap the Susan Wojcicki Foundation aims to fill.

"Lung cancer is being diagnosed too late, for too many people," said Dr. Nadia Litterman, the foundation's executive director. "Susan believed deeply in the power of bringing people together across diverse industries and areas of expertise to solve urgent challenges."

The New Arsenal: AI, Genetics, and Blood Tests

To move beyond the limitations of current screening, the foundation is immediately funding two pioneering projects that leverage cutting-edge science and technology.

The first is a partnership with Brown University and its Health Cancer Institute to establish a first-of-its-kind, multi-site centralized lung cancer biorepository. Crucially, this biobank will be enriched with samples from early-stage and screening-ineligible lung cancer populations. By collecting and studying blood and tissue from the very patients who fall through the cracks of current guidelines, researchers can hunt for the molecular signals that could lead to new diagnostic tools.

The second project involves a collaboration with the International Agency for Research on Cancer (IARC). This research will focus on developing a blood-based test—a form of liquid biopsy—specifically designed to identify people who have never smoked but are at a high risk for lung cancer. Such a test could revolutionize screening, making it more accessible, less invasive, and applicable to a much broader population.

These initiatives align directly with the support from Google.org, which will focus on harnessing AI to analyze complex datasets from sources like these, identifying patterns and risk factors that are invisible to the human eye. The goal is to create a new paradigm where risk is not just defined by smoking history but by a sophisticated understanding of genetics, environment, and molecular biology.

A Blueprint for Collaborative Disruption

Rather than creating another siloed research entity, the Susan Wojcicki Foundation is built on a model of radical collaboration. It is already working alongside established leaders like Stand Up To Cancer and the Lung Cancer Research Foundation, aiming to accelerate progress rather than duplicate efforts.

Its governance structure reflects this modern, integrated approach. Beyond a scientific advisory committee of top researchers, the foundation has also established patient community and creator advisory councils. The patient council ensures the lived experience of those affected by the disease remains central to the mission. The creator council, a clear nod to Susan Wojcicki's legacy at YouTube, will work with YouTube Health and influential online personalities to broaden public awareness and combat misinformation.

This structure represents a new blueprint for tackling major health crises—one that seamlessly integrates high-level science, technological innovation, philanthropic capital, and broad-based public education.

"We are at a remarkable moment where advances in science, technology, and philanthropy are converging in ways that could fundamentally change the future of lung cancer," said Litterman. "The time is now." With real momentum and powerful allies, the foundation is poised to honor its namesake's legacy by ensuring far fewer families experience the devastating loss of a loved one to this disease.